Open Access<p>Patient Satisfaction with Fentanyl Pectin Nasal Spray in Breakthrough Cancer Pain Management During Radiotherapy for Head and Neck Cancer</p>
Author(s) -
Y. Pointreau,
René-Jean Bensadoun,
G. Béra,
C. Siré,
A. Ruffier,
G. Janoray,
G. Calais,
Marc A. Bollet,
B. Pinel,
Viorica Braniste,
Xavier Amores
Publication year - 2020
Publication title -
patient preference and adherence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.885
H-Index - 48
ISSN - 1177-889X
DOI - 10.2147/ppa.s246757
Subject(s) - medicine , tolerability , adverse effect , head and neck cancer , radiation therapy , cancer pain , fentanyl , nasal spray , patient satisfaction , quality of life (healthcare) , anxiety , cancer , anesthesia , surgery , nasal administration , pharmacology , psychiatry , nursing
The severity of breakthrough cancer pain (BTcP) impacts patients' quality of life, increases the risk of anxiety and depression, lowers functional capacities, and may lead to poor compliance with cancer treatments. The aim of the current study was to assess, in a real-life setting, patient satisfaction with a fentanyl-pectin-nasal-spray (FPNS) for BTcP management in head and neck (H&N) cancer patients treated by radiotherapy.